"AbbVie reported a revenue of $15 billion, up 12.4% year over year, with immunology being the top driver, generating $7.3 billion in revenue."
"As a Dividend King, the stock has a yield of 3.27% and a payout ratio of 66%, with an annual payout of $6.92 per share."
"AbbVie raised the full-year revenue guidance to $67.3 billion and increased the adjusted EPS guidance to $14.08-$14.28, up by $300 million from the previous guidance."
Dividend stocks are essential for long-term investing, especially during market volatility. AbbVie stands out with a strong revenue growth of 12.4% year over year, driven by its diverse drug portfolio. The company has raised its revenue and EPS guidance, showcasing its resilience. With a dividend yield of 3.27% and a history of increasing dividends for 12 years, AbbVie is positioned as a reliable investment. Despite a year-to-date decline, its fundamentals suggest potential for appreciation and continued shareholder rewards.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]